Johnson & Johnson and JPMorgan Chase Miss Q3 Earnings Expectations
Johnson & Johnson and JPMorgan Chase both fell short of Q3 EPS estimates, with JNJ special charges and JPMorgan revenue conversion challenges driving the misses.
TLDR
- โJohnson & Johnson Q3 EPS missed estimates; GF Score remains 83/100
- โJPMorgan Chase Q3 EPS fell below consensus despite solid revenue growth
- โJNJ special charges offset strong operational results in the quarter
Why this matters
Coverage sentiment: Bearish ( bullish ยท neutral ยท bearish)
What to watch
- โข Whether JNJ Q4 special charges recur or normalize earnings trajectory
- โข JPMorgan expense management and credit provisioning commentary for Q4
Ripple effects
- โข Large-cap healthcare and banking ETFs may face modest pressure from dual misses
AI-Synthesized news from multiple sources
This article was synthesized by AI from the source articles listed below, reviewed by a second-pass AI quality reviewer, and published by the market.news editorial system. How we do this ยท Editorial standards ยท Report an error
The Quick Take
- Johnson & Johnson Q3 EPS missed estimates; GF Score remains 83/100
- JPMorgan Chase Q3 EPS fell below consensus despite solid revenue growth
- JNJ special charges offset strong operational results in the quarter
- Both blue-chips face headwinds despite underlying business strength
The third quarter of 2026 proved challenging for two blue-chip stalwarts as Johnson & Johnson and JPMorgan Chase both reported earnings misses. Johnson & Johnson's healthcare operations continued to perform solidly on an operational basis, though special charges weighed on the reported EPS figure. JPMorgan Chase demonstrated revenue growth but faced difficulties converting top-line gains into bottom-line beats. These two misses from widely-held index components drew attention to the gap between operational performance and reported earnings, highlighting the impact of one-time items and special charges on headline numbers.
โJPMorgan Chase demonstrated revenue growth but faced difficulties converting top-line gains into bottom-line beats.โ
Johnson & Johnson's GF Score of 83 out of 100 indicates the company retains strong fundamentals despite the Q3 miss, suggesting the shortfall may reflect timing of special charges rather than operational deterioration. JPMorgan's solid revenue growth alongside its earnings miss presents a mixed picture for large-cap banking investors. Holders of JNJ may take comfort in the company's enduring quality metrics, while JPM shareholders face uncertainty about the path from revenue strength to earnings conversion. The misses from these two major index constituents created modest downside pressure on financial and healthcare sector sentiment.
JNJ's 83 GF Score provides a floor of quality confidence for long-term investors, but the market will focus on whether special charges recur in Q4 2026 or represent an isolated item. JPMorgan's challenges in converting revenue growth to earnings beats will prompt scrutiny of expense management and credit provisioning in coming quarters. Both companies' forward guidance and Q4 outlooks will be critical market-moving events. Investors tracking the broader financial sector should weigh whether these misses reflect company-specific issues or signal a more systemic earnings pressure building among large-cap U.S. corporations.
Synthesized from 2 source(s).
Market Intelligence Panel
Coverage
livesources covering this story
Live Price
TVC:DXY๐ Ripple Effects
- โธLarge-cap healthcare and banking ETFs may face modest pressure from dual misses
- โธJNJ GF Score of 83 limits downside for long-term quality investors
- โธJPMorgan miss despite revenue growth may weigh on bank sector sentiment
๐ญ What to Watch Next
PRO- โธWhether JNJ Q4 special charges recur or normalize earnings trajectory
- โธJPMorgan expense management and credit provisioning commentary for Q4
- โธBroader large-cap financial sector earnings trend through season end
How the Story Spread
2 publishers covering this story
AI synthesis of every source listed below. Tier 1 = wire services (AP, Reuters via wire, Bloomberg, official central banks). Tier 2 = major financial publishers. Tier 3 = niche / specialist outlets. Click any card to read the original article.
โ Tier 3 โ Niche & specialist
Is Johnson & Johnson (JNJ) Overvalued After Q3 Earnings Miss? GF Score: 83/100, EPS at $0. ...
Strong Operational Results Offset Special Charges Related Stocks: JNJ,
Is JPMorgan Chase & Co (JPM) Overvalued After Q3 Earnings Miss? EPS at $5. ...
Solid Revenue Growth, Yet Challenges Remain Related Stocks: JPM,
Get the Daily Briefing
Pre-market analysis every morning at 6am ET. Free.
Was this article useful?
Anonymous ยท helps us tune the editorial system
More ๐บ๐ธ United States Stories
PropNotes Upgrades Marvell Technology (MRVL) to Buy on AI Chip Demand Surge
Analyst firm PropNotes upgraded Marvell Technology to Buy, citing surging AI chip demand and Marvell's custom ASIC positioning as a key beneficiary within the hyperscaler AI infrastructure supply chain.
Oct 14, 2026
๐บ๐ธ United StatesUnitedHealth (UNH) Raises 2026 Earnings Guidance After Broad Q3 Beat Across Metrics
UnitedHealth Group raised its 2026 annual earnings guidance after a strong Q3 beat, with four separate coverage pieces highlighting the institutional significance of the guidance lift for the managed care sector.
Oct 14, 2026
๐บ๐ธ United StatesJPMorgan Chase (JPM) Q3 Fixed Income Revenue Misses Estimates, Yet Shares Gain 1.4%
JPMorgan Chase Q3 fixed income trading revenue fell short of analyst estimates, but shares gained 1.4% as investors assessed the broader earnings quality and strength in other business lines.
Oct 14, 2026